Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Vertex Pharmaceuticals Inc. Revenue & Financial Statements
Vertex Pharmaceuticals Inc. reported revenue of $12.0B for the fiscal year ended December 31, 2025, up 8.9% year over year, with net income of $4.0B and diluted EPS of $15.32.
- Company
- Vertex Pharmaceuticals Inc. VRTX · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 7.6B | 8.9B | 9.9B | 11.0B | 12.0B |
| Cost of revenue | 904.2M | 1.1B | 1.3B | 1.5B | 1.7B |
| Gross profit | 6.7B | 7.9B | 8.6B | 9.5B | 10.3B |
| Operating income | 2.8B | 4.3B | 3.8B | (232.9M) | 4.2B |
| Pretax income | 2.0B | 3.3B | 3.1B | (1.4B) | 1.8B |
| Net income | 2.3B | 3.3B | 3.6B | (535.6M) | 4.0B |
| Diluted EPS | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 |
| EBITDA | 2.9B | 4.5B | 4.0B | (72.5M) | 4.4B |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.7B | 2.6B | 2.8B | 2.9B | 2.8B | 3.0B | 3.1B | 3.2B |
| Cost of revenue | 342.6M | 371.9M | 392.6M | 423.4M | 363.0M | 407.5M | 414.8M | 466.0M |
| Gross profit | 2.3B | 2.3B | 2.4B | 2.5B | 2.4B | 2.6B | 2.7B | 2.7B |
| Operating income | 1.1B | (3.5B) | 1.1B | 1.0B | 630.1M | 1.2B | 1.2B | 1.2B |
| Pretax income | 1.3B | (3.4B) | 1.2B | 1.1B | 730.4M | 1.3B | 1.3B | 1.3B |
| Net income | 1.1B | (3.6B) | 1.0B | 913.0M | 646.3M | 1.0B | 1.1B | 1.2B |
| Diluted EPS | 4.21 | -13.92 | 4.01 | 3.53 | 2.49 | 3.99 | 4.20 | 4.64 |
| EBITDA | 1.2B | — | 1.2B | 1.1B | 678.5M | 1.2B | 1.2B | 1.3B |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 13.4B | 18.2B | 22.7B | 22.5B | 25.6B |
| Current assets | 9.6B | 13.2B | 14.1B | 9.6B | 11.2B |
| Cash & equivalents | 6.8B | 10.5B | 10.4B | 4.6B | 5.1B |
| Total liabilities | 3.3B | 4.2B | 5.1B | 6.1B | 7.0B |
| Current liabilities | 2.1B | 2.7B | 3.5B | 3.6B | 3.9B |
| Long-term debt | — | — | — | — | — |
| Total debt | — | — | — | — | — |
| Stockholders’ equity | 10.1B | 13.9B | 17.6B | 16.4B | 18.7B |
| Net debt | — | — | — | — | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 2.6B | 4.1B | 3.5B | (492.6M) | 3.6B |
| Investing cash flow | (340.9M) | (321.1M) | (3.1B) | (3.8B) | (945.4M) |
| Financing cash flow | (1.5B) | (67.7M) | (562.2M) | (1.5B) | (2.3B) |
| Capital expenditure | 235.0M | 204.7M | 200.4M | 297.7M | 437.6M |
| Free cash flow | 2.4B | 3.9B | 3.3B | (790.3M) | 3.2B |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 441.4M | 491.3M | 581.2M | 698.5M | 685.9M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every VRTX filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.